AACR data hint BioNTech on path to clearing two industry hurdles 

The first look at Phase I/II data for BNT211 from BioNTech at the AACR annual meeting suggests the biotech may be on a path to solving two major industry challenges: translating CAR T cells to solid tumors and finding an effective application for cancer vaccines.

BNT211 from  BioNTech SE (NASDAQ:BNTX) pairs an autologous CAR T cell therapy against CLDN6 with an RNA vaccine encoding CLDN6 that’s designed to amplify the CAR T cell response against the target. ...